
<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=undefined&type=result"></script>');
-->
</script> Copyright policy )
 Copyright policy )Diffuse fibrosing sarcoidosis represents an important predisposing factor for infection by Aspergillus sp. The clinical features and specific complications are illustrated by 3 case reports.Patients with chronic fibrosing sarcoidosis and cystic changes or cavitation in the upper lobes are the most prone to aspergillosis. Aspergilloma is the most common form and can be difficult to distinguish from chronic necrotising aspergillosis. Sarcoidosis with aspergillosis is associated with an increased incidence of respiratory failure and fatal haemoptysis. The 3 cases presented in this paper also illustrate the poor efficacy of oral antifungal drugs and bronchial embolisation. Surgery is often necessary but may be difficult on account of the extent of the lesions and poor respiratory function.In the future the use of new drugs such as voriconazole and posaconazole may improve the prognosis of this complication.Aspergillosis represents a frequent complication of diffuse fibrosing sarcoidosis which warrants early detection and treatment on account of its poor prognosis.
MESH: Sarcoidosis, Adult, Male, Hemoptysis, Antifungal Agents, MESH: Lung Diseases, Immunocompromised Host, MESH: Embolization, Sarcoidosis, Pulmonary, MESH: Immunocompromised Host, Aspergillosis, Humans, MESH: Aspergillosis, MESH: Humans, MESH: Middle Aged, Lung Diseases, Fungal, MESH: Hemoptysis, MESH: Adult, Pulmonary, Middle Aged, MESH: Antifungal Agents, Embolization, Therapeutic, MESH: Male, Fungal, Therapeutic
MESH: Sarcoidosis, Adult, Male, Hemoptysis, Antifungal Agents, MESH: Lung Diseases, Immunocompromised Host, MESH: Embolization, Sarcoidosis, Pulmonary, MESH: Immunocompromised Host, Aspergillosis, Humans, MESH: Aspergillosis, MESH: Humans, MESH: Middle Aged, Lung Diseases, Fungal, MESH: Hemoptysis, MESH: Adult, Pulmonary, Middle Aged, MESH: Antifungal Agents, Embolization, Therapeutic, MESH: Male, Fungal, Therapeutic
| citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 20 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% | 
